A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 928 participants.
Also called NCT05362058
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 928 participants
- Sponsor
- Registry
-
NCT05362058 -
2021-005891-21
-
- Other papers using this trial's data
- Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Canada, China, Czechia, Germany, Greece, Japan, Mexico, Puerto Rico, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05362058. Randomized; no masking; primary purpose treatment. Start 2022-06-03 (actual); primary completion 2024-04-10 (actual). Results posted on 2025-05-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
- Acronym
- QWINT-2
- Condition
- Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Insulin Efsitora Alfa
- Intervention (Drug)
- Insulin Degludec
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05362058- Content hash
d19f70d68f684b7950e5d13da53747a61f44076c5f5282c53655706e8d8021a4